Findings of this biomarker substudy suggest that changes in ICAM-1, MMP-3, IL-6, VEGF and CRP levels may be useful markers to evaluate response to infliximab therapy in patients with JIA and thus may enable early identification of patients who could benefit from this treatment. Here, ICAM1 is linked to juvenile idiopathic arthritis.